The purpose of this study is to examine the effect of empagliflozin, with and without
pancreatic clamp, on endogenous (hepatic) glucose production (EGP, or 6,6, D2-glucose),
gluconeogenesis (D2O), lipolysis (U-2H-glycerol), ketogenesis (13C-palmitate conversion to
3-betahydroxybutyrate), and norepinephrine turnover (3H-NE) in type 2 diabetes subjects.
Phase:
Early Phase 1
Details
Lead Sponsor:
The University of Texas Health Science Center at San Antonio
Collaborator:
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)